Karim Amrane

439 total citations
18 papers, 133 citations indexed

About

Karim Amrane is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Karim Amrane has authored 18 papers receiving a total of 133 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Karim Amrane's work include Cancer Immunotherapy and Biomarkers (11 papers), Lung Cancer Treatments and Mutations (7 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Karim Amrane is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Lung Cancer Treatments and Mutations (7 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Karim Amrane collaborates with scholars based in France, United States and Spain. Karim Amrane's co-authors include Ronan Abgral, Ulrike Schick, Gilles Quéré, S. Gouva, C. Chouaïd, R. Descourt, R. Corre, Margaux Geier, G. Robinet and Nathalie Keromnes and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Annals of Oncology.

In The Last Decade

Karim Amrane

15 papers receiving 132 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karim Amrane France 5 105 70 26 20 19 18 133
Ilias Houda Netherlands 6 108 1.0× 80 1.1× 27 1.0× 13 0.7× 16 0.8× 13 141
J. De Langen Netherlands 7 124 1.2× 99 1.4× 20 0.8× 32 1.6× 28 1.5× 18 159
Ornella Cantale Italy 7 127 1.2× 69 1.0× 18 0.7× 26 1.3× 16 0.8× 13 168
Julia Dudnik Israel 9 86 0.8× 89 1.3× 17 0.7× 8 0.4× 32 1.7× 23 143
Carl Cook United States 8 93 0.9× 41 0.6× 24 0.9× 12 0.6× 59 3.1× 12 137
N. Girard France 4 81 0.8× 73 1.0× 19 0.7× 11 0.6× 10 0.5× 24 110
Margaux Geier France 8 167 1.6× 150 2.1× 18 0.7× 18 0.9× 23 1.2× 41 220
Wenqin Feng United States 5 124 1.2× 75 1.1× 12 0.5× 48 2.4× 30 1.6× 9 149
Joanna Wójcik-Tomaszewska United States 3 225 2.1× 131 1.9× 55 2.1× 17 0.8× 18 0.9× 3 255
Leonardo Forero United States 4 66 0.6× 39 0.6× 15 0.6× 21 1.1× 47 2.5× 7 113

Countries citing papers authored by Karim Amrane

Since Specialization
Citations

This map shows the geographic impact of Karim Amrane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karim Amrane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karim Amrane more than expected).

Fields of papers citing papers by Karim Amrane

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karim Amrane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karim Amrane. The network helps show where Karim Amrane may publish in the future.

Co-authorship network of co-authors of Karim Amrane

This figure shows the co-authorship network connecting the top 25 collaborators of Karim Amrane. A scholar is included among the top collaborators of Karim Amrane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karim Amrane. Karim Amrane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Amrane, Karim, Patrice Hémon, Ronan Abgral, et al.. (2025). MHC class II: a predictor of outcome in melanoma treated with immune checkpoint inhibitors. Melanoma Research. 35(3). 176–186.
2.
Amrane, Karim, Benjamin Besse, Patrice Hémon, et al.. (2024). HLA-DR expression in melanoma: from misleading therapeutic target to potential immunotherapy biomarker. Frontiers in Immunology. 14. 1285895–1285895. 14 indexed citations
3.
Masip, J. Remon, Carole Hélissey, Nathalie Cozic, et al.. (2024). 106TiP PULSE, a non-inferiority study of maintenance pembrolizumab at usual or low dose in non-squamous lung cancer. ESMO Open. 9. 102685–102685. 1 indexed citations
4.
Doubre, H., Laurent Greillier, Charles Ricordel, et al.. (2023). Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer. Journal of Cancer Research and Clinical Oncology. 149(16). 15095–15102. 2 indexed citations
5.
6.
7.
Thuillier, Philippe, David Bourhis, Jean Philippe Metges, et al.. (2021). Prospective study of dynamic whole-body 68Ga-DOTATOC-PET/CT acquisition in patients with well-differentiated neuroendocrine tumors. Scientific Reports. 11(1). 4727–4727. 2 indexed citations
8.
9.
10.
Alhalabi, Omar, Laure Hirsch, Elshad Hasanov, et al.. (2021). Efficacy of cabozantinib in advanced MiT family translocation renal cell carcinomas (TRCC).. Journal of Clinical Oncology. 39(6_suppl). 274–274. 10 indexed citations
11.
Geier, Margaux, R. Descourt, R. Corre, et al.. (2020). Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer. Cancer Medicine. 9(19). 6923–6932. 4 indexed citations
12.
Amrane, Karim, et al.. (2020). Incidental Findings of a Vestibular Schwannoma on 18F-Choline PET/CT. Clinical Nuclear Medicine. 46(2). e75–e77. 1 indexed citations
13.
14.
Amrane, Karim, Margaux Geier, R. Corre, et al.. (2020). First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study. Cancer Medicine. 9(7). 2309–2316. 40 indexed citations
15.
Amrane, Karim, Gilles Quéré, S. Gouva, et al.. (2019). Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma. Medicine. 98(29). e16417–e16417. 29 indexed citations
16.
Amrane, Karim, Margaux Geier, R. Corre, et al.. (2019). First line pembrolizumab for NSCLC with PD-L1 TPS > 50% in a first French real life cohort. Annals of Oncology. 30. v617–v617.
17.
Amrane, Karim, S. Querellou, Ulrike Schick, Ronan Abgral, & Jean‐Philippe Metges. (2019). Complete Metabolic Response Assessed by FDG PET/CT to Paclitaxel-Ramucirumab in Patients With Metastatic Gastroesophageal Junction Cancer. Clinical Nuclear Medicine. 45(2). 127–128. 2 indexed citations
18.
Amrane, Karim, Luc Ollivier, Pierre‐Yves Salaün, Jean‐Philippe Metges, & Ronan Abgral. (2019). Complete Metabolic Response Assessed by FDG PET/CT to FOLFIRI-Aflibercept in Second-Line Treatment of Metastatic Colorectal Cancer. Clinical Nuclear Medicine. 44(7). 578–579. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ilias Houda Breakdown of academic impact, for papers by J. De Langen Breakdown of academic impact, for papers by Ornella Cantale Breakdown of academic impact, for papers by Julia Dudnik Breakdown of academic impact, for papers by Carl Cook Breakdown of academic impact, for papers by N. Girard Breakdown of academic impact, for papers by Margaux Geier Breakdown of academic impact, for papers by Wenqin Feng Breakdown of academic impact, for papers by Joanna Wójcik-Tomaszewska Breakdown of academic impact, for papers by Leonardo Forero
Rankless by CCL
2026